DMAC DiaMedica Therapeutics Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$7.08

Period return

-1.25 (-15.01%)

Volume

101.4K

2026-07-21O $6.98 H $7.14 L $6.98 C $7.08MA5 $7.23MA20 $7.25MA60 $6.39MA120 $6.91

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 06.High3 months ago
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2025. 11. 14.MediumBUY8 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2025. 08. 15.LowBUY11 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 07. 19.LowBUYlast year
Craig-Hallum: Buy
US analyst rating / recommendation change.
2025. 07. 19.LowBUYlast year
Lake Street: Buy
US analyst rating / recommendation change.
2025. 07. 18.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 05. 29.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 03. 19.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2024. 11. 15.LowBUY2 years ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2024. 10. 10.LowBUY2 years ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $15.5 · 4 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Sector: Healthcare
Industry: Biotechnology
HQ: Minneapolis, MN, United States
Fiscal year end: —
Employees: 35
IPO date: —

View details →

DiaMedica Therapeutics Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2025. 11. 14.	Cantor Fitzgerald	—	Initiate coverage	— → Overweight	—	Cantor Fitzgerald: Overweight
2025. 08. 15.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 07. 19.	Craig-Hallum	—	Maintain	Buy → Buy	—	Craig-Hallum: Buy
2025. 07. 19.	Lake Street	—	Maintain	Buy → Buy	—	Lake Street: Buy
2025. 07. 18.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 05. 29.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy